

DAFTAR PUSTAKA

- American Joint Committee (2009). Diakses 21 Maret, 2016, from <https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf>.
- ((RSKD), R. (2002). *Pentalaksanaan Kanker Payudara Terkini/Tim Penanggulangan & Pelayanan Kanker Payudara Terpadu Paripurna* (1st ed., Vol. I). Jakarta: Pustaka Populer Obor.
- American Joint Committee on Cancer 7th. (2010). *Breast Cancer Staging 7th ed.* Retrieved April 2, 2016, from <https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf>
- Aryandono. (2006). *Semakin Tinggi Penderita Kanker Payudara di Usia Muda.* Retrieved Maret 20, 2016, from <http://ugm.ac.id/id/berita/1811-semakin.tinggi.penderita.kanker.payudara.di.usia.muda>
- Ayadi, L., & Khabir, A. (2008). *Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian Breast Carcinoma*, 112. Retrieved from <http://www.wjso.com>
- Ayadi, L., & Khabir, A. (2008). Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. *World Journal of Surgical Oncology*.
- Bouchbika, Z., Benchakroun, N., & Taleb, A. (2012). Association between Overexpression of HER-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco.
- Cho. (n.d.). *Structure of the extracelullar region of HER2 alone and in complex with the Herceptin Fab.* 2003.
- CL, C., & LC, C. (2005). *Molecular Targets in Oncology: Signal Transduction System* (VII ed.). Lippincot-Raven.
- Committee, A. J. (2009). Retrieved Maret 21, 2016, from <https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf>.

- Curigliano, G., & Viale, G. (2009). Clinical Relevance of HER-2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. *Journal of Clinical Oncology*.
- DiLeo, D. M.-L. (2002). *Current status of HER-2 testing*, 25-32.
- Fan, Y. X. (2008). Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. 1588-1596.
- Farzami, M., Anjarani, S., & Safadel, N. (2008). Association between the expression of hormone receptors, HER-2/neu overexpression and tumor characteristics in women with primary breast cancer. *The Internet Journal of Pathology Volume 8 Number 2*.
- Gautam K. Malhotra, X. Z. (2010). Histological, Molecular and Functional Subtypes. 956.
- Globocan. (2012). *Cancer Fact Sheets*. Retrieved Maret 20, 2016, from http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- GLOBOCAN. (2012). *International Agency for Reasearch on Cancer*. Retrieved March 23, 2015, from GLOBOCAN 2012 IARC: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- Gray, M., & Gallick, G. (2010). *The role of oncogene activation in tumor progression*, 19-22.
- Greulich, H. K. (2012). *Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2*. U. S. A.
- Grushko, T., & Olopaeda, O. (2008). *Genetic Markers in Breast Tumors With Hereditary Predisposition*, 85-93.
- Harris, L., Fritsche, H., & Menzel, R. (2007). *Journal of Clinical Oncology. Update of Recommendation for the Use of Tumor Marker in Breast Cancer*, 25. Retrieved April 4, 2016, from <http://www.jco.ascopubs.org>
- Institute, N. C. (2015). *What is cancer ?* Retrieved Maret 20, 2016, from <http://www.cancer.gov/cancertopics/what-is-cancer>.

- Junquera, L., & Carneiro, J. (2007). *Histologi Dasar Teks dan Atlas* (10th ed.). Jakarta: EGC.
- Kamarlis, R. K. (2009). *Tampilan Imunohistokimia HER-2/neu Pada Biopsi Aspirasi Jarum Halus Penderita Kanker Payudara*, 45-48.
- KPKN, K. (2015). *Panduan Nasional Pembangunan Kanker Payudara*. Retrieved Maret 20, 2016, from <https://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>
- Kresna, S. B. (2014). *Biomarker Keganasan* (1st ed.). Jakarta: Badan Penerbit FKUI.
- Kumar, V. A. (2015). *Robbins and Kontran Pathologic Basic of Disease* (9th ed.). Philadelphia: Elsevier Saunders.
- Lee. (2006). *Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas*.
- Lina, M. (2004). *Kanker pada Wanita: Pencegahan dan Pengobatan dengan Tanaman Obat*. Jakarta: Penebar Swadaya.
- Mahir, W., Rouss, L., & Ouzir, M. (2016). Correlation of ER, PR, and HER-2 with clinico-pathological parameters in infiltrating Ductal Carcinoma of Breast in Morocco.
- Maimun, M. (2013). *Payudarapedia*. Retrieved from Anatomi dan Fisiologi Payudara: <http://payudarapedia.blogspot.co.id/2013/05/anatomi-dan-fisiologi-payudara.html>
- Mane, A. (2015). *A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Woman*, 1.
- Mary, C., & Lori J., G. (2016). *Prognostic and Predictive Factors in Early-Stage Breast Cancer*. Retrieved April 4, 2016, from <http://theoncologist.alphamedpress.org/content/9/6/606.full>
- Moonkhouse, S. (2007). *Clinical Anatomy* (2nd ed.). China: Churchill Livingstone Elsevier.

- Notoatmodjo, S. (2010). *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- NPD, W. (2014). *In Situ Hybridization pada Kanker Payudara*. Retrieved from <http://journal.uui.ac.id/index.php/JKKI/article/view/3392/3041>
- Otto, S. (2001). *Oncology Nursing* (4th ed.). Mosby years book.
- Payne, S., Bowen, R., Jones, J., & Wells, C. (2008). *Predictive Marker in Breast Cancer The Present*, 82-90.
- Pedersen. (2009). *A naturally occuring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis*.
- Price, S., & Wilson, L. (2005). *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. Jakarta: EGC.
- Pringgoutomo, S., Himawan, S., & Tjarta, A. (2002). *Buku Ajar Patologi I (UMUM)* (1st ed.). Jakarta: Sagung Seto.
- Rahman, A. (2014). *Hubungan Ekspresi HER-2/neu dan Hormonal Reseptor Dengan Grading Histopatologi Pada Penderita Kanker Payudara Wanita Usia Muda*.
- Ramli, M., Umbas, R., & Panigoro, S. (2000). *Deteksi Dini Kanker*.
- RI, P. D. (2015). Retrieved Maret 20, 2016, from <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>.
- Sabiston, A. (2011). *Buku Ajar Bedah I*. Jakarta: EGC.
- Sastroasmoro, S., & Ismael, S. (2011). *Dasar-Dasar Metodologi Penelitian Klinis* (4th ed.). Jakarta: Sagung Seto.
- Sjamsuhidajat, R., & de Jong, W. (2010). *Buku Ajar Ilmu Bedah*. Jakarta: EGC.
- Smith, S. J. (2001). *Breast Cancer: Neu Oppurtunity and Neu Challenges*, 213-219.

- Stephens, P. H. (2004). intragenic ERBB2 kinase mutations in tumors. *Lung cancer*, 525-526.
- Tanto, C., L., F., & H., S. (2014). *Kapita Selekt Kedokteran*. Jakarta: Media Aesculapius.
- Tjahdadi, V. (2008). *Kanker Payudara*. Retrieved Maret 20, 2016, from http://bima.ipb.ac.id/~anita/kanker_payudara.htm
- UNDIP, T. K. (2006). Kanker Payudara Wanita. *Ekspresi Reseptor Estrogen, Reseptor Progesteron dan HER-2*. Retrieved Maret 24, 2016, from www.m3undip.org/ed3/artikel_t
- Wahid, S., Miskad, U. A., & Djimahit, T. (2008). Ekspresi HER-2/neu pada Kanker Payudara. *Korelasi Bermakna Dengan Grading Histopatologi*. Retrieved Maret 20, 2016, from http://www.med.unhas.ac.id/journal/dmdocuments/journal_2008
- Wan, D. (2011). *Buku Ajar Onkologi Klinis* (2nd ed.). Jakarta: Balai Penerbit FK UI.
- WHO. (2013). *Cancer Fact Sheet*. Retrieved Maret 20, 2016, from http://www.searo.who.int/entity/noncommunicable_diseases/advocacy/cancer_fact_sheet.pdf?ua=1.
- William, H. (2004). *Profil Gena HER-2/neu pada Penderita Kanker Payudara di Makassar*.
- World Health Organization. (2015). *World Health Organization*. Retrieved March 17, 2015, from World Health Organization: <http://www.who.int/cancer/detection/breastcancer/en/>